Search results: (10000)
News Idarucizumab reverses the anticoagulant effect of dabigatran even in patients with impaired renal function – clinical practice commentary
Along with the results of a subanalysis of the RE-VERSE AD study, which demonstrated the efficacy of idarucizumab in reversing the anticoagulant effect of dabigatran regardless of the level of renal function impairment, the October issue of the Journal of the American College of Cardiology also featured an editorial commentary by Californian cardiologists on its conclusions.
News Can NOACs 'Compete' with Well-Managed Warfarin Treatment? Retrospective Data from Swedish Registers
The efficacy and safety of new oral anticoagulants (NOACs) in stroke prevention in atrial fibrillation have been proven by numerous studies. The quality of warfarin treatment, assessed by the 'time in therapeutic range' (TTR), ranged between 55% and 65% in these studies. The work of Swedish authors provides a comparison of patients treated with NOACs to a group on warfarin whose average TTR reached 70%.
News Metformin in New European Guidelines for Treating Patients with Diabetes and Cardiovascular Disease
The position of metformin has changed in the guidelines for the treatment of prediabetes and type 2 diabetes in individuals with cardiovascular (CV) disease, issued by the European Society of Cardiology (ESC) in collaboration with the European Association for the Study of Diabetes (EASD) in 2019. The 2019 EASD recommendations differ somewhat, thus we provide the following updated summary.
News Persistence of Treatment with Secukinumab and Ixekizumab in Patients with Moderate to Severe Psoriasis
Although IL-17 targeted drugs are increasingly used in the treatment of moderate to severe psoriasis, we currently have limited data on patient persistence with these treatments.
News European Survey on Prophylactic Treatment of Chemotherapy-Induced Nausea and Vomiting Suggests Gaps in Practice and Ways to Improve
Using recommended guidelines for antiemetic prophylaxis can prevent chemotherapy-induced nausea and vomiting (CINV). Nurses play a significant role in administering prophylactic treatment for CINV. Therefore, a survey was conducted in 16 European countries among middle medical personnel to evaluate the use of recommended antiemetic prophylaxis in oncology practice and the obstacles to its administration.
News New drugs in CLL may also carry specific risks of adverse effects. How to minimize and manage them?
The possibilities for the treatment of chronic lymphocytic leukemia (CLL) have greatly expanded in recent years. Significant changes have been brought particularly by small molecule-based therapeutic agents (inhibitors), which have shown significant efficacy in both previously untreated patients and those who have relapsed from CLL. When choosing the best treatment strategy for patients with CLL, it is of course necessary to consider the specific adverse effects of both new and previously used drugs, the overall condition of the patient, comorbidities, and the so-called individual risk of serious side effects of the drugs.
News Prognostic Significance of Subclinical Joint Changes on MRI in Hemophilia
Experience shows that monitoring joint changes, especially subclinical ones, is very necessary in the care of hemophiliacs. Unfortunately, conventional X-rays cannot detect early changes in joints. Magnetic resonance imaging (MRI) plays an indispensable role in detecting these changes.
News Type of Pharmacological Thromboprophylaxis and Disease Stage as Risk Factors for Bleeding in Patients After Colorectal Cancer Surgery
Japanese authors of a study published last year in the World Journal of Surgical Oncology attempted to answer the question of whether the incidence of postoperative bleeding in patients undergoing elective surgery for colorectal cancer is associated with the type of pharmacological prophylaxis or the disease stage.
News Direct Comparison of Ixekizumab and Adalimumab in Patients with Psoriatic Arthritis
The final results of the direct comparison of ixekizumab and adalimumab in the therapy of biologic-naïve patients with psoriatic arthritis were presented at the annual conference of the American College of Rheumatology (ACR/ARP) in November 2019 in Atlanta.
News Forgotten Pulmonologists: COVID-19 Detection in Patients with Lung Disease
The Czech Pneumological and Phthisiological Society of ČLS JEP (ČPFS) submitted a request to the Ministry of Health of the Czech Republic on March 25, 2020, to allow pulmonologists to send patients with suspected COVID-19 directly for infection testing. In their statement, they also provide recommendations on how to manage care for patients with chronic lung diseases during the outbreak of the SARS-CoV-2 virus and how these patients should behave.
News Prevalence of Diabetics Among Patients with COVID-19 and the Impact of DM on the Course of Infection
Italian authors published the results of a meta-analysis of studies at the end of March, assessing the prevalence of diabetes among individuals infected with SARS-CoV2 and the impact of diabetes on the severity and progression of the infection.
News Obinutuzumab and Early Progression of Patients with Previously Untreated Follicular Lymphoma − Analysis of Data from the GALLIUM Study
The GALLIUM study demonstrated longer progression-free survival (PFS) in patients with previously untreated follicular lymphoma (FL) treated with obinutuzumab compared to rituximab. The aim of the exploratory data analysis was to evaluate the impact of obinutuzumab on the incidence of early disease progression and the relationship between early progression and overall survival (OS) of the patients.
News Comparison of Efficacy of Ixekizumab and Adalimumab in Patients with Psoriatic Arthritis and Moderate to Severe Psoriasis
Ixekizumab, a humanized monoclonal antibody against interleukin 17A (IL-17A), is approved in the Czech Republic for the treatment of active psoriatic arthritis (PsA) and moderate to severe plaque psoriasis. Its efficacy compared to adalimumab in PsA was evaluated in the head-to-head SPIRIT-H2H study. A post-hoc analysis of this study focusing on a subpopulation of patients with PsA and concurrent moderate to severe plaque psoriasis was presented at the Congress of the European Academy of Dermatology and Venereology (EADV) in October 2019 in Madrid.
News Comparison of the Efficacy and Safety of Two Enoxaparin Dosing Regimens in Patients After Chest Surgery
Effective prevention of thromboembolic disease in patients undergoing chest surgery is one of the key therapeutic goals. However, the question remains as to what dose of low molecular weight heparin is optimal for these individuals. A multicenter clinical trial compared the efficacy of a fixed dose of enoxaparin to a weight-adjusted dose.
News Thromboprophylaxis in Cancer Patients − Results of Current Meta-Analysis
A recently published meta-analysis shows the benefits of thromboprophylaxis in cancer patients, with no increased risk of severe bleeding complications.
News Empagliflozin in the Treatment of Patients with Chronic Heart Failure
Unlike other antidiabetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization due to heart failure and the risk of severe renal events in patients with type 2 diabetes mellitus. The efficacy of the SGLT2 inhibitor empagliflozin directly in the treatment of patients with chronic heart failure with reduced ejection fraction was evaluated in the EMPEROR-Reduced clinical study, the recently published results of which we summarize in the following article.
News Intracranial Activity of Lorlatinib in Patients with Metastatic ALK-Positive NSCLC
Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor with significant antitumor activity against non-small cell lung cancer (NSCLC). According to the results of an international clinical study published in the Annals of Oncology, it shows very good efficacy in treating intracranial metastases in patients who experienced disease progression during therapy with second-generation ALK inhibitors.
News Perioperative substitution therapy in patients with vWD must be tailored
Even in cases of von Willebrand disease (vWD), available data supports the need for individualized approaches in ensuring surgical procedures to prevent FVIII accumulation and high factor consumption.
News Another Piece of the Puzzle for More Accurate Dosing of Clotting Factors in von Willebrand Disease
A study published last year in the Journal of Thrombosis and Haemostasis presents the results of Dutch hematologists who created a pharmacokinetic model to refine the dosing of clotting factors during surgery in patients with von Willebrand disease (vWD).
News Safety and Effectiveness of Lurasidone in Adolescents with Schizophrenia
An open-label extension of a placebo-controlled study involving 271 patients aged 13–17 years with schizophrenia showed minimal impact on body weight, lipid levels, prolactin, and blood glucose during 2 years of treatment while maintaining and deepening the alleviation of schizophrenia symptoms.
News Can sartans improve clinical outcomes in hypertensive patients with COVID-19?
Dysfunction of the renin-angiotensin system (RAS) has been detected in patients with COVID-19. This finding led to the hypothesis that RAS inhibitors (RASi) could help these patients. To verify this, a retrospective study was conducted, the results of which we briefly summarize.
News Does idarucizumab reverse the anticoagulant effect of dabigatran regardless of renal function?
The drugs idarucizumab and dabigatran are excreted by the kidneys. The RE-VERSE AD study investigated whether the renal function of patients affects the extent of the reversing effect of idarucizumab on the effect of dabigatran.
News New Treatment Option for Metastatic Pancreatic Cancer – Pegylated Liposomal Irinotecan
The 2019 review article is dedicated to the use of nanoliposomal irinotecan, its toxicity, and its potential use in the treatment sequence of metastatic pancreatic ductal adenocarcinoma.
News Sport as an Important Part of the Life of Hemophiliacs
People with congenital bleeding disorders have very diverse approaches to sports and exercise. The possibility of preventing bleeding by administering safe and effective medications for these patients clearly supports engagement in an active physical life.
News Can Co-administration of Dabigatran with Antiretroviral Drugs Be Effective and Safe?
In 2019, the first results regarding the concurrent use of antiretroviral drugs and oral anticoagulants were published. This involved 14 patients with atrial fibrillation and HIV infection, in whom the concurrent administration of dabigatran with antiretroviral drugs was not associated with the occurrence of thromboembolic events or bleeding during follow-up lasting up to 40 months.